Pulmonx (LUNG)
(Real Time Quote from BATS)
$8.16 USD
-0.20 (-2.39%)
Updated Jul 23, 2024 10:48 AM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LUNG 8.16 -0.20(-2.39%)
Will LUNG be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LUNG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LUNG
5 Medical Info Systems Stock to Buy for a Stable Portfolio
How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%
LUNG: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Medical Info Systems Stocks to Buy for Stable Returns
Wall Street Analysts See a 56.11% Upside in Pulmonx (LUNG): Can the Stock Really Move This High?
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
Other News for LUNG
Pulmonx: Low Bar For Q2 Earnings
Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
What's Driving Silk Road Medical Inc's Surprising 37% Stock Rally?
Pulmonx initiated with bullish view at Lake Street, here's why
SBRA, GH and CRBU are among after hour movers